BioClonal proposes collaborations with pharma industry to improve any monoclonal antibodies therapy
2023 Feb 20
We believe in our technology as the solution that will help patients and pharma industry by improving any TherapeuticmAbs treatment. That's why we are developing our own FirstInClass for Alzheimer's disease, based on a new approach not yet experimented.
in addition to its own developments, BioClonal proposes a collaborative effort to address the scientific challenges of this time by leveraging the strengths of our nnovative "in vivo" platform RedMabs and expertise of our mAbs specialized team.
in addition to its own developments, BioClonal proposes a collaborative effort to address the scientific challenges of this time by leveraging the strengths of our nnovative "in vivo" platform RedMabs and expertise of our mAbs specialized team.
Paula Garfella Lorente, C.E.O. & Co-Founder of BioClonal explains the company's objectives and philosophy.
Ver en Youtube
